{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:27:24Z","timestamp":1794000444352,"version":"4.8.0"},"reference-count":60,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This study is the first large-scale, head-to-head comparison suggesting that sodium-glucose cotransporter-2 inhibitors (SGLT2is) may offer greater neuroprotection against Parkinson's disease (PD) compared to metformin in patients with type 2 diabetes mellitus (T2DM). Utilizing a 20-year real-world dataset and propensity score matching, we found that SGLT2i users had a 28% lower adjusted hazard ratio (aHR) for PD (0.72; 95% CI, 0.62\u20130.84) and reduced all-cause mortality. Unlike previous studies suggesting a potential increased PD risk with SGLT2is, our robust study design, stringent exclusion criteria, and competing risk adjustments support a protective association. The findings highlight the need for further prospective research to explore the neuroprotective benefits of SGLT2is, which may justify prioritizing their use in T2DM patients at risk for neurodegeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) is linked to an increased risk of Parkinson's disease (PD), likely mediated by insulin resistance, inflammation, and mitochondrial dysfunction. While metformin has shown neuroprotective effects, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerging benefits in neurodegeneration. This study provides the first real-world head-to-head comparison of SGLT2is and metformin on PD risk in T2DM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the TriNetX platform, we analyzed a 20-year dataset (2005\u20132025) from 142 healthcare organizations, identifying 913,428 T2DM patients (96,018 SGLT2i, 817,410 metformin users). Patients with prior PD, neurodegenerative diseases, or exposure to neuroprotective\/neurotoxic antidiabetic drugs were excluded. Propensity score matching (1:1) balanced cohorts across demographic, clinical, and pharmacological variables. Cox proportional hazards models estimated adjusted hazard ratios (aHRs), validated by positive and negative controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SGLT2i use was associated with a 28% lower PD risk than metformin (aHR\u2009=\u20090.72; 95% CI, 0.62\u20130.84; p\u2009&lt;\u20090.0001). Dementia, a positive control, also showed reduced risk (aHR\u2009=\u20090.73; 95% CI, 0.68\u20130.78; p\u2009&lt;\u20090.0001), reinforcing the neuroprotective effect. Negative controls confirmed specificity. SGLT2i users had significantly lower all-cause mortality (aHR\u2009=\u20090.85; 95% CI, 0.83\u20130.89; p\u2009&lt;\u20090.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first large-scale comparison suggests SGLT2is provide superior neuroprotection against PD compared to metformin in T2DM patients, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x251359391","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T07:26:35Z","timestamp":1752737195000},"page":"1240-1252","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes"],"prefix":"10.1177","volume":"15","author":[{"given":"Mingyang","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"},{"name":"Academy of Medical Sciences of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"},{"name":"Academy of Medical Sciences of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengrong","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan"},{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Yuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan"},{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan"},{"name":"Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan"},{"name":"Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan"},{"name":"Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan"},{"name":"Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-9644","authenticated-orcid":false,"given":"Jiaqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191900"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1922"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0688"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1333"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005771"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28551"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168838"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101727"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00302"},{"key":"e_1_3_3_12_2","article-title":"Two birds one stone: the neuroprotective effect of antidiabetic agents on parkinson disease-focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors","volume":"10","author":"Lin KJ","year":"2021","unstructured":"Lin KJ, Wang TJ, Chen SD, et al. Two birds one stone: the neuroprotective effect of antidiabetic agents on parkinson disease-focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. Antioxidants (Basel) 2021; 10.","journal-title":"Antioxidants (Basel)"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00410-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0117-1"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29298"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1244022"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176117"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000129"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.838173"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad366"},{"key":"e_1_3_3_21_2","article-title":"Metformin use and risk of delirium in older adults with type 2 diabetes","author":"Sun M","year":"2024","unstructured":"Sun M, Wang X, Lu Z, et al. Metformin use and risk of delirium in older adults with type 2 diabetes. Diabetes Care 2024.","journal-title":"Diabetes Care"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104593"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678649"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001370"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.03.010"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050946"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024954"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010398"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573399813666170816142351"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_85_17"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101623"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081750"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.747620"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01538-1"},{"key":"e_1_3_3_36_2","article-title":"Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan","author":"Chuang WL","year":"2024","unstructured":"Chuang WL, Tsai SC, Yang YC, et al. Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan. Naunyn Schmiedebergs Arch Pharmacol 2024.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/db24-916-P"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148536"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.03.005"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00440"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108173"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009838117"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.07.046"},{"key":"e_1_3_3_44_2","first-page":"27","article-title":"The potential role of metformin in the treatment of Parkinson\u2019s disease","volume":"3","author":"Lu M","year":"2020","unstructured":"Lu M, Chen H, Nie F, et al. The potential role of metformin in the treatment of Parkinson\u2019s disease. J Bio-X Res 2020; 3: 27\u201335.","journal-title":"J Bio-X Res"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00084-5"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17570"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002947"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1705"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/1028415X.2023.2192561"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2021.05.011"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-006-9018-6"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26760"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.01.015"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26477"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0154-3"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm318"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.020"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20341"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3624"},{"key":"e_1_3_3_61_2","article-title":"The healthy user effect in pharmacoepidemiology","author":"Olawore O","year":"2024","unstructured":"Olawore O, Stupsilonrmer T, Glynn RJ, et al. The healthy user effect in pharmacoepidemiology. Am J Epidemiol 2024.","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251359391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251359391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251359391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:51:51Z","timestamp":1777589511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251359391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/1877718X251359391"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251359391","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}